Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis
Jean‐Jacques Kiladjian(Délégation Paris 5), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Francesco Passamonti(University of Milan), Daniel B. Lipka(German Cancer Research Center), Suddhasatta Acharyya(Novartis (United States)), Vincent Ribrag(Institut Gustave Roussy), Eibhlin Conneally(St. James's Hospital), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Song Mu, Sabine Loechner, Florian H. Heidel(Medizinische Hochschule Hannover), Bruno Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Amjad Hayat(Ollscoil na Gaillimhe – University of Galway), Thomas Kindler(German Cancer Research Center), Prashanth Gopalakrishna(Novartis (Switzerland)), Susan Ide(Novartis (United States))
Cited by 14
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k